ADC Name,Description,Mechanism,Indications,Clinical Dose Range Tested,Recommended Phase II Dose (RP2D),Notes
TUB-030,ADC with an exatecan payload,Delivers cytotoxic agent to 5T4-expressing cells,"Advanced solid tumors (e.g., prostate cancer)",0.5 - 2.5 mg/kg every 3 weeks,1.5 mg/kg every 3 weeks,Dosing based on safety and tolerability outcomes from Phase I trials.
ASN004,"Novel ADC targeting 5T4, using Dolaflexin-cleavable linkers and auristatin derivatives",Delivers cytotoxic agent effectively,"Breast, non-small cell lung, colorectal, ovarian cancers",1.0 - 3.0 mg/kg every 2 weeks,2.5 mg/kg every 2 weeks,RP2D determined after evaluating pharmacokinetics and toxicity.
PF-06263507,Anti-5T4 humanized ADC with MMAF payload,Delivers cytotoxic agent,"Non-small cell lung cancer, breast cancer, ovarian cancer",0.1 - 3.0 mg/kg weekly,Not established (terminated),RP2D not applicable due to discontinuation for safety issues.
SYD1875,ADC comprising a humanized anti-5T4 antibody and duocarmycin analog,Delivers cytotoxic agent,Solid tumors,0.1 - 2.5 mg/kg every 3 weeks,1.0 mg/kg every 3 weeks,RP2D based on tolerability and preliminary efficacy signals.
IBR854,CAR-NK cell therapy targeting 5T4,Links 5T4 antibody with NK cells,Solid tumors,1.0 - 3.0 mg/kg weekly,Not established (early-phase trials),"Due to the unique nature of the therapy, RP2D has not been finalized."
